ILB^® resolves inflammatory scarring and promotes functional tissue repair.

Area of Science:

• Biomedical Science
• Pharmacology
• Regenerative Medicine

Background:

• Fibrotic diseases are a leading cause of mortality globally, characterized by chronic inflammation and abnormal extracellular matrix deposition.
• Current therapies for fibrotic and inflammatory conditions have limited success, highlighting a significant unmet medical need.
• Dysfunctional tissue repair mechanisms contribute to persistent inflammation and fibrosis, leading to loss of organ function.

Purpose of the Study:

• To investigate the therapeutic potential of a novel low molecular weight dextran sulfate (LMW-DS), designated ILB®, in resolving inflammation and promoting tissue repair.
• To evaluate the efficacy of ILB® in preclinical models of fibrotic disease.
• To elucidate the molecular mechanisms underlying ILB®'s anti-fibrotic and regenerative effects.

Main Methods:

• In vitro studies assessing the modulation of pro-inflammatory cytokines and chemokines by ILB®.
• In vivo studies using rodent and human disease models to evaluate scar resolution and matrix remodeling.
• Analysis of gene expression changes, including transforming growth factor (TGF)β signaling and extracellular matrix dynamics.

Main Results:

• ILB® demonstrated significant modulation of pro-inflammatory cytokine and chemokine expression in vitro.
• In vivo studies showed scar resolution and improved matrix remodeling in disease models treated with ILB®.
• ILB® was found to downregulate TGF-β signaling and alter genes involved in extracellular matrix dynamics, promoting tissue regeneration.

Conclusions:

• ILB® effectively resolves inflammation and promotes scar tissue remodeling, leading to functional tissue regeneration.
• The compound's mechanism involves downregulating TGF-β signaling and modulating extracellular matrix gene expression.
• ILB® presents a promising therapeutic candidate for alleviating fibrotic diseases with potential for improved tissue homeostasis.